Why Oncotarget Continues to Thrive in the World of Medical Information

Oncotarget in a weekly peer reviewed journal that publishes research articles every week with a focus on oncology and cancer research. This is the journal’s primary focus. The journal concentrates on information for its readers most of whom are scholars and people in the medical world about the progress in this complex tumor development with integrity. It also publishes papers in the fields of endocrinology, physiology, age related studies, as well as pathology and immunology.In as much as Oncotraget focuses on oncology, its published papers go beyond this subject. It has sections with advisory and editorial boards on the following subjects: aging/gerotarget, immunology, autophagy, cell disease, chromosomes, and all disciplines of oncology. Also, coming soon are publishing in the fields of neuro science and stem cells.

If you are interested in posting a cancer research paper that is not based or related to oncology, then you are advised to select a relevant section that it could fit. If none exists, there is the option of choosing to post in the others section. For any editorial post, choose a section that is titled editorial regardless of the subject.Oncotarget was established in 2010 in the bid to gather all useful information in the medical field especially those related to oncology in one platform. It is published by impact journals.Its chief editors Mikhail Blagoslonny and Andrei V. Gudvok from the Rosewell Park Cancer Institute.Oncotarget is well known for publishing credible articles whose research has been well done.

One such research is the effect of E-cigarettes on from the University of Rochester Medical Center. This study revealed that the use of E-cigs also has an adverse impact on the gums and general oral health as it causes harm just as conventional cigarettes do.This is a study that was carried out by Professor Irfan Rahman whose specialty is environmental medicine at the UR School of Medicine and Dentistry. For the longest time, doctors thought that the smoke found in conventional cigarettes was what caused the problems related to oral health, but recent research including this one on e-cigs proves otherwise. The research has shown that when the vapors from the cigarettes are released, they cause inflammations of proteins, which in turn strains the cells which then causes damage that could trigger oral infections including gum diseases.

Jason Hope, a philanthropist with a passion for technology

When you hear about the Internet of things, the first person that comes to mind is Jason Hope. Jason Hope famous philanthropist. Jason Hope is an investor and an entrepreneur, who resides in Scottsdale in Arizona. He achieved his finance degree at the Arizona State University. He also holds an MBA from the W.P. Carey School of Business. Jason is a strong believer in giving back to his community. He has been spotted speaking instilling knowledge to high school students. He also has a program that offers grants to entrepreneurs. Jason Hope also has an eye on great ideas. He digs into the submitted ideas and hand selects the great ones, which he later assists in funding for their startups.

Jason Hope is a philanthropist who is very passionate about technology. He recently funded the SENS Foundation with half a million dollars to continue with their research on how to better age-related diseases. This Foundation works towards a better and accessible solution to age related diseases, through rejuvenation biotechnologies. Hope was particularly interested in this Foundation because it uses technology to better human lives.

Jason Hope has played a key role in the development of the Internet of Things, the technology that gives the ability to synchronize devices that use the internet. Jason, the futurist, has predicted that the Internet of Things will be a big game changer in future. Most companies will have to take it on as everything will be dependent on it. The pace setter companies around the world have already embraced the Internet of Things, and soon their competitors will have to catch up, in order to keep up with the growing wants and needs in the market to learn more: https://www.crunchbase.com/person/jason-hope#/entity click here.

Jason Hope has founded and invested in a couple of companies which he earns from. His companies use advanced technology to run their day to day activities. Jason advises anyone willing to start out a business or is in business, to use the social media as a marketing tool. He insists and stands firm that this is an efficient and fast way to market your product. He also encourages entrepreneurs to tackle one product or service at a time, in order to become successful.

Get Rid of Your Physic Insecurity with Dr. Jennifer Walden

Most of the people have that part of their body that they have always wished appeared differently than how it looks like in the real sense. Many individuals live with this feeling of dissatisfaction almost all their life. Discontentment in physical appearance can be disturbing and could lead to some insecurities. These uncertainties result in reduced level of productivity. For instance, many people will have a problem standing in front of people to discuss or prove a point, because they feel inadequate and like everyone is judging them based on their weakness. This is why Dr. Jennifer Walden, a cosmetic surgeon, advises people to drop the fear and get the surgery done to continue with a healthy life.

Many individuals who undergo this problem are aware of the surgeon’s solution but are afraid of how results may turn out. In the reviews, of Dr. Jennifer Walden Reviews, her patients say that they were scared of the outcome but the great talks that they received from the nurses and the surgeon herself gave them the confidence to go ahead and have the surgery.

The patience says that Dr. Walden’s unit is full of welcoming nurses and staff. In their reviews, her patients say that they received nothing but warm compassion from the time they entered that gate. It is this kind treatment they received that assured them they were in good hands.

Dr. Jennifer Walden has very positive reviews from her patients. Many of her patients say that reason they signed in with her was somehow influenced by the reviews that they saw from her other patients as they proudly posted their before and after pictures. Fortunately, the patients are grateful and feel good to have stopped being wishful spectators to being the lucky patients sending the reviews. They highly recommend anyone in need of cosmetic surgery to visit Dr. Jennifer Walden.

http://blogwebpedia.com/dr-jennifer-walden-reviewing-best-cosmetic-procedures.html/

Amicus Therapeutics Is Positioned At The Front Line For Advancing Therapies

Global biotechnology company Amicus Therapeutics makes the most of its one of a kind platform technologies and medicines to deliver benefits to the rare and orphan disease community.

 

In late stage development, Amicus Therapeutics lead product candidate, migalastat, will treat people with Fabry disease based on their genetic diagnosis (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/). Another lead product candidate, SD-101, designed to gain consumer confidence, is a therapy for the uncommon hereditary connective tissue disorder Epidermolysis Bullosa.

 

In addition, Amicus Therapeutics is also driving novel enzyme replacement therapy brands for Pompe disease, Fabry disease, and other illnesses.

 

John Crowley, chairman and chief executive officer at Amicus Therapeutics emphasized what differentiates Amicus Therapeutics from other companies is how it keeps up an empathetic and caring focus on not only its patients but also their caregivers and families.

 

He explained how that point of view is built into everything from team meetings to the board of directors. He added the company also tries to base its decisions as if they were undergoing treatment themselves.

 

Expanding on its patient-centric perspective, Amicus Therapeutics acquired

privately-held biopharmaceutical company, Scioderm in 2015. Crowley said in a statement the acquisition is an excellent strategic match to build advanced therapies for both devastating unusual and orphan diseases.

 

In 2013, Amicus Therapeutics acquired privately-held competitor Callidus Biopharma, which focuses on enzyme replacement therapies (ERTs)for Pompe disease, according to (en.wikipedia.org/wiki/Amicus_Therapeutics).

 

Amicus Therapeutics said it will take part in a conference call and live audio webcast on August 7 to talk about the financial results for the second quarter ended June 30, 2017.

 

Crowley will moderate the call and additional members of his team will also participate in the event.

 

According to PR Newswire, Amicus Therapeutics stock surged 48.78 percent in the last month and 80.08 percent over the previous three months (PhillyPurge).

 

What’s more, Amicus Therapeutics was the recipient of a $500,000 grant from the Michael J. Fox Foundation in 2010 and that same year it received a $210,300 grant from the Alzheimer’s Drug Discovery Foundation.

 

Amicus Therapeutics, which was founded in 2002, is based in Cranbury, New Jersey. The company has a second research site in San Diego, California.

 

Bob Reina: It Is Time To Start Over

Bob Reina believes in the power of people starting over in life. He believes it is never too late for someone to start over and get a fresh start in their life. First and foremost, they need to believe in themselves and they need to believe they can do it. Once they start to believe it, other people will believe it as well. That is half the battle in many of these cases. The old adage goes: if you don’t believe in what you are doing and you don’t believe in yourself, why should others? Once they start believing in themselves and putting their plan into action, they will see truly out of this world results. Learn more: https://homebusinessmag.com/author/bob-reina/

 

That is the goal and that is the dream Bob Reina has for every single user of Talk Fusion, the video communications provider that is top of the line for video, chat, and data. They don’t get any better than them and they can back it up with two awards from 2016 including the 2016 Communications Solutions Product of the Year Award. It is a special award, no question, but then again, Talk Fusion is a special company that people really respect, especially Bob Reina. It is hard not to respect all he has done for the company and for other people such as his charitable donation to the Tampa Bay Humane Society. Learn more: http://blog.talkfusion.com/

 

This is in addition to the thirty day free trials the company offers to new customers that want to try out Talk Fusion for the first time and see all it has for the customers. At the end of the day, Bob Reina is a good man, and there are not enough good men out there walking around among us. That is not meant as a simplified statement. It is the truth. Because he is a good man, people see all he is doing and they want to find out how they can do something similar to make the world a better place today than it was yesterday.

 

Bob Reina has inspired people, and he does so every single day, which is no small feat. Learn more: http://inspirery.com/bob-reina/

The Trajectory of Canadian Businessman Louis Chenevert

If you haven’t heard of Louis Chenevert, he was previously at the helm of one of the largest U.S manufacturing enterprises, United Technologies Corporation. Chenevert held the title of Chairman and CEO of this $63 billion industrial conglomerate, a role he occupied from 2010 to 2014. Louis Chenevert is a Canadian businessman who was born in Quebec and earned a bachelor of commerce degree in production management from HEC Montreal, an affiliated Business School of the acclaimed University of Montreal. He is well versed in business management and has held an array of high-level positions throughout his career.

CAREER PATH OF LOUIS CHENEVERT
Prior to his role with United Technologies Corporation, Chenevert spent 14 years with General Motors, and during his tenure with the American multinational corporation, he rose to become the production manager for the Ste. Therese, Quebec plant. In 1993, Chenevert joined Pratt and Whitney Canada, an aerospace manufacturer, where he became president of the aircraft engine division in 1999, and ultimately group president and Chief Operating Officer in 2006. So what is the key to success for Louis Chenevert? Chenevert credits “operational focus” as the impetus for his business success; Chenevert looks to drive synergy through reorganization as opposed to acquisition.

CHENEVERT AND GOLDMAN SACHS
So, what is Louis Chenevert doing these days? Well, Goldman, Sachs, and Company have retained him as an advisor for their Merchant Banking Division. In this role, he will be leveraging his experience with United Technologies Corporation to recommend target opportunities in the aerospace and industrial sectors, as well as other businesses. If past success is indicative of his future with Goldman, Sachs, and Company, Chenevert’s advisory role will prove to be a great business decision on the part of the multinational finance company. Chenevert’s passion for business and his keen eye for detail will undoubtedly serve him well in any business endeavor, but for now, he is focused on his future with Goldman Sachs.